Genomics

Dataset Information

0

Fingerprinting of the hNGF P61R100E gene expression in rat Dorsal Root Ganglion detected by microarray analysis


ABSTRACT: Nerve Growth Factor (NGF) is being considered as a therapeutic candidate for Alzheimer's disease (AD) treatment, not merely as a long-lasting cholinergic maintainer and neuroprotective agent but also as a direct anti-amyloidogenic factor. However, the development of a NGF-based therapy for neurodegenerative diseases is limited by the partial access of NGF to the brain and to its potent nociceptive actions in animals and humans. Indeed, NGF is involved in pain transmission and perception. The nociceptive activity of NGF is mediated through the activation of TrkA and p75NTR receptors on sensory nerve endings. Our group recently studied forms of NGF, mutated at residue R100, inspired by the human genetic disease HSAN V (Hereditary Sensory Autonomic Neuropathy Type V), which would allow increasing the dose of NGF without triggering pain. This “painless” hNGF hNGFP61S/R100E displays full neurotrophic and anti-amyloidogenic activities in neuronal cultures, and a reduced nociceptive activity in vivo, via a selective alteration of TrkA versus p75NTR binding and signaling. The molecular mechanism through which pNGF reduces nociceptive activity has never been investigated, therefore we performed gene expression microarray analysis to investigated the effect of hNGF hNGFP61S/R100E delivery in rat Dorsal Root Ganglia.

ORGANISM(S): Rattus norvegicus

PROVIDER: GSE80257 | GEO | 2017/04/18

SECONDARY ACCESSION(S): PRJNA318401

REPOSITORIES: GEO

Similar Datasets

2023-11-27 | GSE245097 | GEO
2013-11-01 | GSE25611 | GEO
2023-11-27 | GSE244921 | GEO
2019-04-05 | GSE118187 | GEO
2013-11-01 | E-GEOD-25611 | biostudies-arrayexpress
2023-11-27 | GSE221035 | GEO
2008-06-11 | E-GEOD-10498 | biostudies-arrayexpress
2011-12-01 | E-GEOD-23530 | biostudies-arrayexpress
2015-05-06 | PXD001115 | Pride
2008-04-09 | GSE10498 | GEO